Skip to main content

Advertisement

Table 2 Analysis of maximum CRT across all treatments

From: A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities

Toxicity n (Univariable analysis) n (Multivariable analysis) BCSS RFS
Unadjusted Adjusted Unadjusted Adjusted
HR (95 % CI) P value HR (95 % CI) P value HR (95 % CI) P value HR (95 % CI) P value
Neutropeniaa 5886 5211 0.85 (0.74–0.98) 0.02 0.87 (0.75–1.01) 0.06 0.85 (0.76–0.95) 0.004 0.86 (0.76–0.97) 0.02
Nausea 6248 5468 1.11 (0.93–1.33) 0.25 1.09 (0.90–1.33) 0.37 1.07 (0.91–1.25) 0.42 1.06 (0.90–1.26) 0.47
Vomiting 6248 5468 0.98 (0.80–1.19) 0.80 1.03 (0.84–1.28) 0.76 1.00 (0.85–1.18) >0.99 1.05 (0.88–1.26) 0.57
Stomatitis 6248 5468 1.20 (0.89–1.63) 0.24 1.25 (0.90–1.74) 0.19 1.09 (0.83–1.43) 0.54 1.12 (0.83–1.50) 0.46
Constipation 5886 5211 0.91 (0.80–1.04) 0.17 0.95 (0.82–1.09) 0.45 0.91 (0.82–1.01) 0.09 0.94 (0.83–1.05) 0.27
Diarrhoea 6248 5468 0.93 (0.68–1.26) 0.64 0.98 (0.70–1.38) 0.93 1.08 (0.85–1.37) 0.54 1.19 (0.92–1.55) 0.18
Infection 6248 5468 1.09 (0.97–1.22) 0.14 1.01 (0.90–1.15) 0.82 1.06 (0.96–1.16) 0.26 1.01 (0.91–1.12) 0.88
Fatigue 6248 5468 1.24 (1.07–1.43) 0.004 1.17 (0.99–1.37) 0.06 1.17 (1.03–1.32) 0.01 1.13 (0.99–1.30) 0.08
Anaemia 3943 3582 1.18 (0.97–1.42) 0.09 1.14 (0.93–1.39) 0.21 1.11 (0.95–1.30) 0.20 1.08 (0.91–1.28) 0.36
Combined haematological 3943 3582 0.89 (0.77–1.03) 0.11 0.88 (0.76–1.03) 0.12 0.88 (0.78–0.99) 0.03 0.88 (0.78–1.00) 0.06
Neurotoxicity 3943 3582 0.96 (0.82–1.13) 0.64 0.99 (0.84–1.17) 0.90 0.98 (0.86–1.12) 0.78 0.99 (0.87–1.14) 0.94
Myalgia 3943 3582 0.95 (0.82–1.09) 0.43 1.03 (0.89–1.20) 0.69 0.95 (0.84–1.06) 0.34 1.02 (0.91–1.16) 0.70
Fever 3943 3582 0.98 (0.67–1.44) 0.91 0.84 (0.57–1.26) 0.41 1.08 (0.80–1.46) 0.63 0.98 (0.71–1.34) 0.88
  1. BCSS Breast cancer-specific survival; RFS Relapse-free survival; HR Hazard ratio; CI Confidence interval
  2. aCases classified as National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAEAE) grade ≥3